Oncolytics Biotech Inc.

Healthcare · Biotechnology · Canada

Last price 0.4254 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 54.24M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated ...